eliquidflavourconcentrates.co.uk — FDA Warning Letter, 2026-07-02: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded
TL;DR
Here's the summary: The FDA Center for Tobacco Products issued a warning letter to eliquidflavourconcentrates.co.uk on July 2, 2026 (MARCS-CMS 733423), finding that the entity sold Bastard Sauce ELFC Longfill and Salt Nicotine e-liquids Kit to a person under age 21, violating section 906(d)(5) of the FD&C Act and rendering the product misbranded under section 903(a)(7)(B). The letter requires a written response within 15 working days describing corrective actions and compliance plans, and warns that failure to address violations may result in civil penalties, seizure, and/or injunction.
Argus analysis
# FDA Warning Letter: eliquidflavourconcentrates.co.uk
On July 2, 2026, the FDA's Center for Tobacco Products issued a warning letter to eliquidflavourconcentrates.co.uk, a UK-based e-liquid manufacturer offering products for sale into the United States. The FDA determined that the company's Bastard Sauce ELFC Longfill and Salt Nicotine e-liquids kit constitutes a tobacco product under federal law because it contains nicotine from any source and is intended for human consumption. The agency's investigation found that the company sold this product to a consumer under 21 years of age through its website, triggering misbranding violations.
The warning cites section 903(a)(7)(B) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 387c(a)(7)(B)) and section 906(d)(5) (21 U.S.C. § 387f(d)(5)). These provisions establish that all nicotine-containing products sold as tobacco products must include age-verification controls at the point of sale, and that any sale to individuals under 21 constitutes misbranding. The citations also reference 21 C.F.R. Parts 1140, 1141, and 1143, which govern tobacco product labeling, advertising, and retailer compliance obligations. Failure to comply with these regulations can result in civil penalties, product seizure, or injunction.
The company had 15 working days from receipt to submit a written response detailing corrective actions and compliance plans to CTPCompliance@fda.hhs.gov (reference number RW2602430). Compliance officers in the e-liquid sector should monitor whether this company achieves closure through demonstrated age-verification implementation on its website, and whether similar enforcement activity follows against other online retailers lacking adequate age-gating mechanisms. The FDA's cc to Google suggests scrutiny of platform-level compliance as well.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Tobacco letters cite the Family Smoking Prevention and Tobacco Control Act, primarily Section 910 (premarket review of new tobacco products) for ENDS / e-vapor SKUs.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER eliquidflavourconcentrates.co.uk MARCS-CMS 733423 — July 02, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Tobacco Recipient: eliquidflavourconcentrates.co.uk United States info@eliquidflavourconcentrates.co.uk Issuing Office: Center for Tobacco Products United States July 2, 2026 WARNING LETTER To Whom It May Concern: The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https://eliquidflavourconcentrates.co.uk and determined that e-liquid products listed there are offered for sale or distribution to consumers in the United States. Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. 1 Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901 of the FD&C Act (21 U.S.C. § 387a) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act. Under section 906(d)(5) of the FD&C Act (21 U.S.C. § 387f(d)(5)), it is unlawful for any retailer 2 to sell a tobacco product to any person younger than 21 years of age. 3 This includes tobacco products containing nicotine from any source including cigarettes, smokeless tobacco, cigars, e-cigarettes, and nicotine pouches. Tobacco Product Sold by a Retailer to an Individual Under the Age of 21 is Misbranded Under section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)), tobacco products are misbranded if sold or distributed by any retailer to a person younger than 21 years of age in violation of section 906(d)(5) of the FD&C Act (21 U.S.C. § 387f(d)(5)). FDA has determined that your Bastard Sauce ELFC Longfill and Salt Nicotine e-liquids Kit is misbranded under section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)) because this product was sold to a person younger than 21 years of age. Specifically, during FDA’s investigation of https://eliquidflavourconcentrates.co.uk, a person younger than 21 years of age purchased Bastard Sauce ELFC Longfill and Salt Nicotine e-liquids Kit from your website. Conclusion and Requested Actions It is your responsibility to ensure that your tobacco products and all related labeling and/or advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and FDA’s implementing regulations, including those in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and/o…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What FDA violations was eliquidflavourconcentrates.co.uk cited for?
- The FDA Warning Letter to eliquidflavourconcentrates.co.uk (issuing office: Center for Tobacco Products) cites: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Classification: Tobacco / ENDS.
- When did FDA issue the warning letter to eliquidflavourconcentrates.co.uk?
- FDA issued the letter (MARCS-CMS 733423) on 2026-07-02 and posted it publicly on fda.gov on 2026-07-14.
- Is the FDA warning letter to eliquidflavourconcentrates.co.uk publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eliquidflavourconcentratescouk-733423-07022026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). eliquidflavourconcentrates.co.uk — FDA Warning Letter, 2026-07-02: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-eliquidflavourconcentrates-co-uk-2026-07-02-tobacco
"eliquidflavourconcentrates.co.uk — FDA Warning Letter, 2026-07-02: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-eliquidflavourconcentrates-co-uk-2026-07-02-tobacco.
Argus HQ Research. "eliquidflavourconcentrates.co.uk — FDA Warning Letter, 2026-07-02: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded." Digital Empire LLC. Accessed July 17, 2026. https://argushq.ai/fda/warning-letter/fda-wl-eliquidflavourconcentrates-co-uk-2026-07-02-tobacco.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_eliquidflavourconcentrates_co_uk_2026_07_02_tobacco_2026,
title = {eliquidflavourconcentrates.co.uk — FDA Warning Letter, 2026-07-02: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-eliquidflavourconcentrates-co-uk-2026-07-02-tobacco},
note = {Accessed: July 17, 2026}
}